Unipol Gruppo S.p.A. Q2 2026 Earnings Recap

Shares declined 1.6% following the release as investors digested solid earnings growth but appeared cautious on the outlook for business growth, particularly noting some deceleration in the Health segment and the prudent tone around investment income sustainability.

Key Takeaways

• Net profit exceeded EUR 900 million, up nearly 50% year-on-year, supported by improved technical profitability in Non-Life and Life segments.
• Non-Life premiums rose by almost 4%, with the combined ratio improving below 92%, signaling disciplined underwriting despite a challenging nat cat environment.
• Life business showed strong premium growth and positive net inflows near EUR 800 million, with improved profitability driven by both technical results and investment income.
• Investment yield (excluding one-off SpaceX mark-to-market) stands close to 6%, but for H2 a more conservative 4–5% yield is expected due to the timing of dividend receipts.
• Health business growth moderated in H1 versus last year, with management cautiously signaling hopes for reacceleration in H2 driven by new large corporate contracts.